Breye Therapeutics, a Danish clinical-stage #biopharmaceutical company developing #oral#therapeutics for the early treatment of #retinal diseases, has closed an oversubscribed €67.5 million Series A financing round. 🇩🇰 👁️ 💊
Glasgow-based @mironidltd, a #biopharmaceutical company, has closed a €39.9 million Series B round to push its lead drug candidate for Autosomal Dominant Polycystic #Kidney#Disease through #clinical development. 🏴 💊 💉
